메뉴 건너뛰기
Chest
Volumn 129, Issue 6, 2006, Pages 1396-1398
Thrombotic end point for assessing argatroban therapy for heparin-induced thrombocytopenia: Learning from secondary analyses of prospective studies
Author keywords

[No Author keywords available]
Indexed keywords

ARGATROBAN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN;
EID: 33745171056     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1396     Document Type: Editorial
Times cited : (1)
References (12)
  • 1
    • 33745173460 scopus 로고    scopus 로고
    • Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia
    • Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129:1407-1416
    • (2006) Chest , vol.129 , pp. 1407-1416
    • Lewis, B.E.1    Wallis, D.E.2    Hursting, M.J.3
  • 2
    • 0035836541 scopus 로고    scopus 로고
    • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
    • Lews BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
    • (2001) Circulation , vol.103 , pp. 1838-1843
    • Lews, B.E.1    Wallis, D.E.2    Berkowitz, S.D.3
  • 3
    • 0038285887 scopus 로고    scopus 로고
    • Argatroban anticoagulation in patients with heparin-induced thrombocytopenia
    • Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856
    • (2003) Arch Intern Med , vol.163 , pp. 1849-1856
    • Lewis, B.E.1    Wallis, D.E.2    Leya, F.3
  • 4
    • 28444447383 scopus 로고    scopus 로고
    • Lepirudin in patients with heparin-induced thrombocytopenia: Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3
    • Lubenow, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3:2428-2436
    • (2005) J Thromb Haemost , vol.3 , pp. 2428-2436
    • Lubenow1    Eichler, P.2    Lietz, T.3
  • 5
    • 28444442250 scopus 로고    scopus 로고
    • Lepirudin: Is the approved dosing schedule too high?
    • Hacquard M, De Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost 2005; 3:2593-2596
    • (2005) J Thromb Haemost , vol.3 , pp. 2593-2596
    • Hacquard, M.1    De Maistre, E.2    Lecompte, T.3
  • 6
    • 0029035681 scopus 로고
    • Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
    • Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
    • (1995) N Engl J Med , vol.332 , pp. 1330-1335
    • Warkentin, T.E.1    Levine, M.N.2    Hirsh, J.3
  • 7
    • 27144527501 scopus 로고    scopus 로고
    • Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis
    • Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710-2715
    • (2005) Blood , vol.106 , pp. 2710-2715
    • Martel, N.1    Lee, J.2    Wells, P.S.3
  • 8
    • 4644242157 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):311S-337S
    • (2004) Chest , vol.126 , Issue.SUPPL.
    • Warkentin, T.E.1    Greinacher, A.2
  • 9
    • 0036733708 scopus 로고    scopus 로고
    • Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia
    • Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71:50-52
    • (2002) Am J Hematol , vol.71 , pp. 50-52
    • Smythe, M.A.1    Warkentin, T.E.2    Stephens, J.L.3
  • 10
    • 27844481103 scopus 로고    scopus 로고
    • Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
    • Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94:958-964
    • (2005) Thromb Haemost , vol.94 , pp. 958-964
    • Warkentin, T.E.1    Greinacher, A.2    Craven, S.3
  • 11
    • 0035082406 scopus 로고    scopus 로고
    • Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin
    • Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85:435-440
    • (2001) Thromb Haemost , vol.85 , pp. 435-440
    • Sheth, S.B.1    Dicicco, R.A.2    Hursting, M.J.3
  • 12
    • 0038285888 scopus 로고    scopus 로고
    • Gender and risk of immune heparin-induced thrombocytopenia
    • Warkentin TE, Sigouin CS. Gender and risk of immune heparin-induced thrombocytopenia [abstract]. Blood 2002; 100(suppl):17a
    • (2002) Blood , vol.100 , Issue.SUPPL.
    • Warkentin, T.E.1    Sigouin, C.S.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.